---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-061978"
form_type: "8-K"
ticker: "JAZZ"
cik: "0001232524"
company_name: "Jazz Pharmaceuticals plc"
filed_at: "2026-09-15T13:06:12+00:00"
generated_at: "2026-09-15T13:07:23.360901+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jazz completes $820M upfront acquisition of Actio Biosciences for KCNT1 epilepsy drug ABS-1230

## Summary
- Jazz completed $820M upfront acquisition of Actio Biosciences; Actio now a wholly-owned subsidiary.
- ABS-1230 is a first-in-class oral KCNT1 inhibitor; inhibited all evaluable mutations in preclinical studies.
- In early clinical proof-of-concept, children with KCNT1-related epilepsy had meaningful seizure reductions.
- FDA granted Fast Track, Rare Pediatric Disease and Orphan Drug designations for ABS-1230.
- Actio spun off non-ABS-1230 programs into a new company; Jazz received a minority stake.

## SEC filing metadata
- accession: 0001628280-26-061978
- form_type: 8-K
- ticker: JAZZ
- cik: 0001232524
- company_name: Jazz Pharmaceuticals plc
- filed_at: 2026-09-15T13:06:12+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1232524/000162828026061978/0001628280-26-061978-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1232524/000162828026061978/jazz-20260915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-061978
- JSON: https://secwatch.observer/filing/0001628280-26-061978.json
- Plain text: https://secwatch.observer/filing/0001628280-26-061978.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.